GlassScriptPhysician profile
Jagdeep Chhindra
NPI 1518026137
$3,738.37
in general payments reported to CMS, 2019-2025
30 companies · $856 in 2025
The $856 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $388 · 2021: $320 · 2022: $377 · 2023: $585 · 2024: $793 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,189 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,188.94 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $489.38 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $423.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $369.61 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $346.58 | 2019-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.50 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $227.59 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $176.52 | 2023-2024 | Glassia |
| Amgen INC. | $158.92 | 2024-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $139.73 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boston Scientific Corporation | $137.87 | 2024-2025 | Watchman Flx |
| Abbvie INC. | $110.54 | 2022-2025 | Qulipta, Ubrelvy |
| Global Blood Therapeutics, INC. | $102.03 | 2020-2022 | |
| Insmed, INC. | $97.97 | 2025 | Arikayce |
| Exact Sciences Corporation | $91.33 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $77.10 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.70 | 2024-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $68.60 | 2024-2025 | |
| Corcept Therapeutics | $52.20 | 2025 | Korlym |
| Janssen Biotech, INC. | $43.45 | 2024 | Rybrevant |
| Medtronic, INC. | $38.26 | 2025 | Interstim, Inceptiv |
| Merck Sharp & Dohme LLC | $37.93 | 2022 | |
| Esperion Therapeutics, INC. | $36.46 | 2024-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $26.40 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.92 | 2025 | |
| Neurelis, INC. | $19.82 | 2023 | Valtoco |
| Nestle Healthcare Nutrition INC. | $17.93 | 2023 | |
| Inspire Medical Systems, INC. | $16.98 | 2024 | Inspire |
| Abbott Laboratories | $15.15 | 2024 | Eterna |
| Kowa Pharmaceuticals America, INC. | $14.82 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jagdeep Chhindra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.